Insulet Valuation
Is PODD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of PODD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PODD ($263.35) is trading above our estimate of fair value ($197.72)
Significantly Below Fair Value: PODD is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PODD?
Key metric: As PODD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is PODD's PE Ratio? | |
|---|---|
| PE Ratio | 43.9x |
| Earnings | US$420.90m |
| Market Cap | US$18.62b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.7x |
| Enterprise Value/EBITDA | 45.2x |
| PEG Ratio | 27.6x |
Price to Earnings Ratio vs Peers
How does PODD's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 56.1x | ||
STE STERIS | 35x | 11.5% | US$20.8b |
DXCM DexCom | 44.6x | 16.6% | US$29.8b |
ZBH Zimmer Biomet Holdings | 19.9x | 8.1% | US$21.3b |
BAX Baxter International | 125.1x | 40.5% | US$15.0b |
PODD Insulet | 43.9x | 1.6% | US$18.6b |
Price-To-Earnings vs Peers: PODD is good value based on its Price-To-Earnings Ratio (43.9x) compared to the peer average (56.1x).
Price to Earnings Ratio vs Industry
How does PODD's PE Ratio compare vs other companies in the US Medical Equipment Industry?
| 4 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
BDMD Baird Medical Investment Holdings | 4.3x | n/a | US$56.89m |
MHUA Meihua International Medical Technologies | 1.4x | n/a | US$12.88m |
PAVM PAVmed | 0.5x | -90.0% | US$7.91m |
RTSL Rapid Therapeutic Science Laboratories | 0.3x | n/a | US$18.99k |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: PODD is expensive based on its Price-To-Earnings Ratio (43.9x) compared to the US Medical Equipment industry average (35.7x).
Price to Earnings Ratio vs Fair Ratio
What is PODD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 43.9x |
| Fair PE Ratio | 27.3x |
Price-To-Earnings vs Fair Ratio: PODD is expensive based on its Price-To-Earnings Ratio (43.9x) compared to the estimated Fair Price-To-Earnings Ratio (27.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$263.35 | US$282.22 +7.2% | 10.1% | US$340.00 | US$234.00 | n/a | 22 |
| Dec ’25 | US$266.78 | US$275.31 +3.2% | 8.0% | US$317.00 | US$234.00 | n/a | 22 |
| Nov ’25 | US$235.61 | US$247.99 +5.3% | 9.3% | US$285.00 | US$185.00 | n/a | 21 |
| Oct ’25 | US$234.56 | US$242.23 +3.3% | 9.2% | US$285.00 | US$185.00 | n/a | 21 |
| Sep ’25 | US$202.77 | US$236.85 +16.8% | 7.4% | US$264.00 | US$185.00 | n/a | 21 |
| Aug ’25 | US$197.25 | US$233.64 +18.4% | 9.0% | US$270.00 | US$185.00 | n/a | 21 |
| Jul ’25 | US$196.16 | US$233.64 +19.1% | 9.0% | US$270.00 | US$185.00 | n/a | 21 |
| Jun ’25 | US$177.19 | US$233.64 +31.9% | 9.0% | US$270.00 | US$185.00 | n/a | 21 |
| May ’25 | US$170.27 | US$236.27 +38.8% | 7.0% | US$270.00 | US$208.00 | n/a | 20 |
| Apr ’25 | US$168.10 | US$236.13 +40.5% | 7.0% | US$270.00 | US$208.00 | n/a | 20 |
| Mar ’25 | US$169.25 | US$236.77 +39.9% | 7.6% | US$270.00 | US$208.00 | n/a | 20 |
| Feb ’25 | US$195.40 | US$232.27 +18.9% | 11.5% | US$270.00 | US$163.00 | n/a | 20 |
| Jan ’25 | US$216.98 | US$226.72 +4.5% | 13.5% | US$270.00 | US$163.00 | n/a | 20 |
| Dec ’24 | US$192.19 | US$219.90 +14.4% | 16.1% | US$280.00 | US$163.00 | US$266.78 | 20 |
| Nov ’24 | US$137.72 | US$251.60 +82.7% | 21.1% | US$355.00 | US$162.00 | US$235.61 | 20 |
| Oct ’24 | US$159.49 | US$273.11 +71.2% | 17.5% | US$355.00 | US$185.00 | US$234.56 | 18 |
| Sep ’24 | US$192.18 | US$287.72 +49.7% | 15.0% | US$355.00 | US$208.00 | US$202.77 | 18 |
| Aug ’24 | US$270.94 | US$345.33 +27.5% | 8.7% | US$375.00 | US$234.00 | US$197.25 | 18 |
| Jul ’24 | US$288.34 | US$345.94 +20.0% | 8.6% | US$375.00 | US$234.00 | US$196.16 | 18 |
| Jun ’24 | US$272.48 | US$345.94 +27.0% | 8.6% | US$375.00 | US$234.00 | US$177.19 | 18 |
| May ’24 | US$318.87 | US$337.18 +5.7% | 8.7% | US$375.00 | US$234.00 | US$170.27 | 17 |
| Apr ’24 | US$318.96 | US$331.00 +3.8% | 9.3% | US$375.00 | US$234.00 | US$168.10 | 16 |
| Mar ’24 | US$282.48 | US$328.75 +16.4% | 9.8% | US$375.00 | US$234.00 | US$169.25 | 16 |
| Feb ’24 | US$290.53 | US$311.63 +7.3% | 11.7% | US$350.00 | US$216.00 | US$195.40 | 16 |
| Jan ’24 | US$294.39 | US$309.94 +5.3% | 12.0% | US$350.00 | US$216.00 | US$216.98 | 16 |
| Dec ’23 | US$308.00 | US$302.13 -1.9% | 12.0% | US$350.00 | US$216.00 | US$192.19 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.